Reviewed evidence dossier / GHK-01
GHK-Cu evidence:
the model sets the boundary.
Cultured fibroblasts and rat wound models report extracellular-matrix observations under defined experimental conditions. This dossier keeps those preclinical findings separate from human clinical outcomes and distinguishes FDA’s route-specific compounding records from product approval.
Defined preclinical observations.
The cited studies support chemical-identity context and measured findings in cultured fibroblasts and rat wound chambers, alongside current FDA route-specific compounding records.
Human outcomes or catalog equivalence.
The record does not establish clinical wound healing, cosmetic effects, systemic benefit, injectable safety, product approval, or the identity and quality of a separate vial.
What kind of answer can this dossier provide?
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. The core experimental record summarized here measures collagen synthesis, extracellular-matrix accumulation, and matrix-remodeling markers in laboratory or animal models. Those endpoints describe the models; they do not establish a corresponding clinical outcome in people.
A chemical record and a regulatory category answer different questions.
PubChem records prezatide copper under CID 71587328. That database record supplies chemical-identity context only. FDA’s current compounding materials separately distinguish GHK-Cu for injectable routes from GHK-Cu except for injectable routes.
FDA’s May 2026 document places “GHK-Cu (except for injectable routes of administration)” in Category 1, meaning under evaluation—not approved. FDA’s separate safety-risk page identifies limited human data and potential immunogenicity concerns for compounded injectable drugs containing GHK-Cu.
Finding, model, limitation, source.
RECORD
Reference chemical identity
PubChem records the copper complex under CID 71587328 and lists names including prezatide copper and GHK-Cu.
Limit: A database identity record does not test or verify a seller’s material, formulation, concentration, stability, or biological equivalence.
CELLS
Collagen synthesis in fibroblast culture
A 1988 experiment reported increased collagen synthesis in cultured fibroblasts exposed to GHK-Cu, without a corresponding change in cell number.
Limit: A cultured-cell response does not establish skin, wound, hair, or connective-tissue outcomes in people.
WOUND MODEL
Extracellular-matrix measurements in wound chambers
A 1993 rat study reported concentration-dependent changes in dry weight, DNA, total protein, collagen, glycosaminoglycans, and selected matrix-related messenger RNAs inside implanted wound chambers.
Limit: An implanted rat wound chamber is not a human clinical wound and does not establish a treatment outcome.
CELLS
Matrix-remodeling markers in dermal fibroblasts
A 2000 study reported changes in MMP-2 messenger RNA and secretion, together with TIMP-1 and TIMP-2 secretion, in cultured dermal fibroblasts.
Limit: Changes in laboratory markers do not establish that remodeling is beneficial, clinically meaningful, or reproduced in people.
ROUTE RECORD
Injectable-route safety questions remain unresolved
FDA’s live safety-risk summary states that compounded injectable drugs containing GHK-Cu may pose immunogenicity risk because of potential aggregation and peptide-related impurities, and that human safety data are limited.
Limit: The page identifies a potential risk and data gap; it does not quantify risk incidence or evaluate a specific commercial vial.
STATUS RECORD
Non-injectable nomination remains under evaluation
FDA’s May 2026 category document lists GHK-Cu except for injectable routes in Category 1 and states that FDA intended to consult its advisory committee before the end of February 2027.
Limit: Category 1 means under evaluation. It is not FDA approval, a final inclusion decision, or evidence of clinical effectiveness.
Questions the cited record does not resolve.
The core sources do not establish clinical wound, skin, hair, or connective-tissue outcomes in people.
Cell and animal experiments do not resolve human exposure, uncommon harms, immunogenicity, or long-term safety for any route.
A change in collagen, MMP, TIMP, or another laboratory marker does not by itself establish a beneficial clinical outcome.
A chemical name or database record does not establish identity, purity, strength, safety, efficacy, approval, or intended use for a seller’s material.
What the model can—and cannot—answer.
What is GHK-Cu?
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. PubChem records the reference chemical under CID 71587328.
What kind of evidence anchors this dossier?
The core outcome evidence consists of cultured-fibroblast experiments and rat wound models. FDA records add current route-specific compounding and safety context; they do not turn preclinical findings into human outcomes.
What did the fibroblast studies measure?
The cited experiments measured collagen synthesis and matrix-remodeling markers including MMP-2, TIMP-1, and TIMP-2 in cultured fibroblasts.
Do the fibroblast and rat-wound findings establish human clinical outcomes?
No. Cultured cells and implanted rat wound chambers answer model-specific questions. They do not establish clinical wound healing, cosmetic effects, or systemic benefit in people.
Does FDA Category 1 mean GHK-Cu is approved?
No. FDA defines Category 1 as bulk drug substances under evaluation. Its May 2026 record lists GHK-Cu except for injectable routes in that category; the status is not FDA approval or a final inclusion decision.
What does FDA say about injectable routes?
FDA’s live safety-risk page identifies potential immunogenicity concerns related to aggregation and peptide-related impurities and states that human safety data are limited. It does not quantify the incidence of harm.
Does this dossier evaluate any PSC catalog vial?
No. A chemical record or published experiment does not establish the identity, purity, strength, safety, efficacy, approval, or intended use of a seller’s material.
Open the model and the route together.
- PubChem · Prezatide copper / GHK-CuChemical-identity record, CID 71587328. Identity context only; not a commercial-material test.PubChem record ↗
- Maquart et al. · FEBS Letters · 1988Collagen-synthesis experiment in cultured fibroblasts · DOI 10.1016/0014-5793(88)80509-X.PubMed 3169264 ↗
- Maquart et al. · Journal of Clinical Investigation · 1993Connective-tissue measurements in implanted rat wound chambers · PMCID PMC288419 · DOI 10.1172/JCI116842.PubMed 8227353 ↗
- Siméon et al. · Life Sciences · 2000MMP-2, TIMP-1, and TIMP-2 observations in cultured dermal fibroblasts · DOI 10.1016/S0024-3205(00)00803-1.PubMed 11045606 ↗
- FDA compounding safety-risk summaryLive agency page describing potential injectable-route immunogenicity concerns and limited human safety data.FDA record ↗
- FDA 503A category document · May 2026Lists GHK-Cu except for injectable routes as Category 1, meaning under evaluation. Not approval or a final inclusion decision.FDA category PDF ↗
Versioned, not silently rewritten.
Version 1.0 published. Added model-labeled fibroblast and rat findings, a chemical-identity boundary, factual FAQs, and explicit route-specific interpretation of current FDA compounding records.
A substantive correction records the date, changed statement, reason, and supporting source. Send a precise citation or correction request through the PSC policies and contact page.